NASDAQ:NBRV Nabriva Therapeutics (NBRV) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsFinancialsInsider TradesSEC FilingsTrendsBuy This Stock About Nabriva Therapeutics Stock (NASDAQ:NBRV) 30 days 90 days 365 days Advanced Chart Remove Ads Get Nabriva Therapeutics alerts:Sign Up Key Stats Today's Range N/A50-Day Range N/A52-Week Range N/AVolumeN/AAverage Volume29,344 shsMarket Capitalization$45.46 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewNabriva Therapeutics plc, a biopharmaceutical company, engages in the development and commercialization of novel anti-infective agents to treat serious infections. The company's product includes SIVEXTRO, an oxazolidinone-class antibacterial for the treatment of acute bacterial skin and skin structure infection (ABSSSI); and XENLETA, a semi-synthetic pleuromutilin antibiotic for oral and IV administration. It also develops XENLETA that is in Phase I clinical trial for the treatment of pediatric infections, as well as sexually transmitted infections, cystic fibrosis, ABSSSI, ventilator-associated bacterial pneumonia, complicated intra-abdominal infections, hospital-acquired bacterial pneumonia, acute bacterial skin and skin structure infections, osteomyelitis, and prosthetic joint infections. In addition, the company develops CONTEPO, an epoxide antibiotic for use in treating complicated urinary tract infections, as well as is in Phase I clinical trial for peri-operative prophylaxis. The company was formerly known as Nabriva Therapeutics Forschungs GmbH and changed its name to Nabriva Therapeutics plc in 2007. Nabriva Therapeutics plc was incorporated in 2005 and is headquartered in Dublin, Ireland.Read More… Remove Ads Receive NBRV Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Nabriva Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address NBRV Stock News HeadlinesNabriva Therapeutics (NASDAQ:NBRV) Coverage Initiated by Analysts at StockNews.comMarch 28, 2025 | americanbankingnews.comNabriva Therapeutics plc (NBRVF)October 19, 2024 | finance.yahoo.comDOGE Social Security bombshell?Elon Musk just dropped another bombshell... He revealed his DOGE organization has been taking aim at Social Security, finding what he says is widespread fraud across the agency.April 4, 2025 | Altimetry (Ad)Nabriva Therapeutics PLC NBRVFApril 13, 2024 | morningstar.comArbutus Biopharma Corporation: Arbutus Appoints Two New ExecutivesJuly 11, 2023 | finanznachrichten.deNBRV - Nabriva Therapeutics plcMay 26, 2023 | finance.yahoo.comBacterial Pneumonia Therapeutics Market Updated Report by Competitor Strategics till 2029February 28, 2023 | marketwatch.comNBRV Nabriva Therapeutics plcFebruary 25, 2023 | seekingalpha.comSee More Headlines NBRV Stock Analysis - Frequently Asked Questions How were Nabriva Therapeutics' earnings last quarter? Nabriva Therapeutics plc (NASDAQ:NBRV) released its quarterly earnings results on Thursday, May, 6th. The biotechnology company reported ($13.25) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($16.75) by $3.50. The biotechnology company earned $2.53 million during the quarter, compared to the consensus estimate of $2.25 million. Nabriva Therapeutics had a negative net margin of 148.11% and a negative trailing twelve-month return on equity of 365.53%. Read the conference call transcript. When did Nabriva Therapeutics' stock split? Shares of Nabriva Therapeutics reverse split before market open on Friday, September 16th 2022. The 1-25 reverse split was announced on Friday, September 16th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Friday, September 16th 2022. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split. How do I buy shares of Nabriva Therapeutics? Shares of NBRV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Nabriva Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Nabriva Therapeutics investors own include SCYNEXIS (SCYX), Vaxart (VXRT), VBI Vaccines (VBIV), Acasti Pharma (ACST), NVIDIA (NVDA), Sorrento Therapeutics (SRNE) and Dynavax Technologies (DVAX). Company Calendar Last Earnings5/06/2021Today4/04/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:NBRV CIK1641640 Webwww.nabriva.com Phone(531) 649-2000Fax610-816-6639Employees70Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($19.20) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-57,190,000.00 Net Margins-148.11% Pretax Margin-144.78% Return on Equity-365.53% Return on Assets-135.81% Debt Debt-to-Equity Ratio0.12 Current Ratio0.85 Quick Ratio0.52 Sales & Book Value Annual Sales$35.59 million Price / Sales0.00 Cash FlowN/A Price / Cash FlowN/A Book Value$0.10 per share Price / BookN/AMiscellaneous Outstanding Shares32,015,000Free Float31,493,000Market Cap$45.46 million OptionableNot Optionable Beta1.53 Social Links Beginner's Guide To Retirement StocksEnter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free Report This page (NASDAQ:NBRV) was last updated on 4/4/2025 by MarketBeat.com Staff From Our PartnersTrump Allies Confirm Exec Order 14024 Triggers Dollar CollapseExecutive Order 14024 is paving the way for irreversible damage to the dollar's value—threatening your wealth,...Priority Gold | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredYour Retirement Is Caught in the CrossfireWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredCaught on Camera: Elon Musk’s “Area 51”You won’t believe what tech legend Jeff Brown found in what he calls Elon Musk’s “Area 51.” (Click here to see...Brownstone Research | SponsoredTrump’s Final Plan Presidential insider exposes shocking plot to reshape U.S. economy: The 2025 Trump Reset -- Inside Trump’...Porter & Company | SponsoredControversial opinion: Volume isn't enough.Don’t be fooled by volume alone — it's just one piece of the trading puzzle. High demand doesn’t matter if sup...MillPub | SponsoredRUTHLESS Musk Move >> coming June 1?Elon Musk has made headlines with everything from mass layoffs to political drama — but his next move could sh...Paradigm Press | SponsoredNearly $3 Trillion Gone…Nearly $3 trillion disappeared from the stock market on Thursday morning. According to Whitney Tilson - a f...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Nabriva Therapeutics plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Nabriva Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.